Our efficacy trained methods are applicable to any drug target, but as highlighted in our invited submission to Nature Biopharmaceutical Dealmakers (featured in Nature Reviews Drug Discovery and Nature Biotechnology),  Azor was founded to design small molecules able to target microRNA and monitor their efficacy, however, the platform is target-agnostic and validated across diverse drug target classes.  

The current market for RNA-targeted small molecules is valued over $113-billion, with only four established drug targets. Azor Biotek's innovative approach allows for the design of novel molecules to target any RNA — opening many previously inaccessible avenues for therapeutic development as every disease has multiple unexploited RNA drug targets .

Our philosophy of what constitutes the targetable transcriptome